Lab21 expands genetic testing deal with PGxHealth
This article was originally published in Clinica
Diagnostic firm Lab21 has extended its partnership with the genomic testing unit of Clinical Data in order to offer its customers a wider range of genetic tests. Cambridge, UK-based Lab21 had an existing licence with Clinical Data’s PGxHealth subsidiary to exclusively market the Familion portfolio of mutation tests in the UK and Ireland, but has now added assays for catecholaminergic polymorphic ventricular tachycardia (CPVT) and hypertrophic cardiomyopathy (HCM) to its remit. The CPVT and HCM assays are compatible with the Familion platform and will also be marketed in the UK and Ireland. Financial terms of the deal were not revealed.